Amycretin Zenagamtide GLP-1/Amylin Data 2026

What is Amycretin (Zenagamtide)?

Amycretin is a unimolecular dual agonist that activates both GLP-1 and amylin receptors. Novo Nordisk’s next-generation obesity agent is now formally named zenagamtide — its international nonproprietary name (INN); amycretin (development codes NNC0487-0111 / NN9487) was the original name and is still widely used. Same molecule, two labels.

The key distinction: most dual-pathway obesity approaches combine two separate drugs (as CagriSema does with semaglutide plus cagrilintide). Amycretin attempts to deliver both GLP-1 and amylin activity from a single molecule. That difference has potential implications for dosing, manufacturing, and potentially tolerability — though these remain to be demonstrated in Phase 3 data. For a direct head-to-head breakdown, see our amycretin vs CagriSema comparison.

What Weight-Loss Data Has Zenagamtide Shown?

Novo Nordisk’s Phase 2 trial in type 2 diabetes presented at the ADA 2026 Scientific Sessions showed once-weekly subcutaneous zenagamtide produced weight loss of up to 14.6% at week 36 on the highest 40 mg dose (vs 2.1% on placebo), alongside dose-dependent HbA1c reductions of up to 1.71 percentage points from a 7.8% baseline, with 89.1% of participants reaching HbA1c below 7% (source).

These figures come from type 2 diabetes Phase 2 work, not a completed Phase 3 obesity readout. Zenagamtide should be characterised as a high-conviction late-pipeline asset — not a proven market-ready obesity compound. Our CagriSema amylin and GLP-1 profile covers the more advanced combination approach targeting the same biology.

Why Is Amycretin Trending in 2026?

Novo Nordisk’s 2025 annual report and February 2026 investor presentation position amycretin as one of the company’s major follow-on assets in obesity and diabetes after semaglutide — specifically as the post-2027 obesity follow-on to CagriSema in the Novo pipeline. The compound has now entered its Phase 3 AMAZE programme for obesity, and in May 2026 Novo launched AMAZE-12, a Phase 3 trial of amycretin for weight maintenance after diet-induced weight loss — the first amycretin Phase 3 obesity-maintenance study (ClinicalTrials.gov NCT07503210). Track all key trial milestones on our obesity drug approval tracker for 2026.

Regional context: in May 2026 Novo Nordisk announced a UAE logistics hub, flagging the Middle East as a growth region for its obesity portfolio (source). The hub is logistics scope — not a UAE clinical or regulatory milestone for amycretin specifically — but it signals where Novo expects demand for the next-generation obesity portfolio to grow.

The question has shifted from what is this early asset? to could this become one of Novo’s next flagship obesity medicines? For supplier verification around the current retatrutide research market, see our best retatrutide supplier guide.

Is Zenagamtide the Same as CagriSema?

No. This is the most important distinction to understand.

CagriSema combines semaglutide (a GLP-1 agonist) and cagrilintide (an amylin analog) as two separate active components in a fixed-dose combination. Zenagamtide is a single molecule engineered to activate both GLP-1 and amylin pathways simultaneously.

They target the same biology through fundamentally different molecular architectures. That distinction matters for dosing flexibility, manufacturing complexity, and potentially tolerability and adherence. For context on how both compare with triple-agonist candidates, see our retatrutide vs tirzepatide vs CagriSema analysis.

What Still Needs to Be Proven?

Three open questions define the zenagamtide narrative heading into Phase 3:

1. Obesity efficacy at scale — Will Phase 3 weight-loss data match the mechanistic expectations?

2. Oral vs subcutaneous positioning — Will the two formulations target different populations or indications?

3. Unimolecular vs combination — Will a single-molecule approach compete effectively against CagriSema’s combination strategy?

Novo Nordisk’s Amycretin Pipeline — Phase III Programme & Development Timeline

SC Amycretin — Subcutaneous Phase III Trials

Novo Nordisk has confirmed that SC amycretin (the once-weekly subcutaneous amycretin formulation) is in Phase III trials for obesity under the AMAZE programme. The Novo Nordisk Phase III programme for SC amycretin is expected to enrol thousands of patients with overweight or obesity across multiple global trial sites. The primary endpoint for these Phase III trials will likely mirror standard obesity drug development requirements: percentage change in body weight from baseline compared with placebo at 68 weeks.

In May 2026 Novo Nordisk launched AMAZE-12, a Phase 3 trial of amycretin specifically for weight maintenance after diet-induced weight loss — the first amycretin Phase 3 obesity-maintenance trial (ClinicalTrials.gov NCT07503210). Maintenance after diet-induced weight loss is a distinct regulatory and commercial use case from initial weight reduction, and it broadens the amycretin label envelope Novo is preparing.

The Danish drugmaker’s Phase III programme for amycretin represents one of the company’s largest pipeline investments. Internally, Novo positions amycretin as the post-2027 obesity follow-on to CagriSema (source). Novo Nordisk has demonstrated in Phase II that SC amycretin delivers clinically meaningful weight loss in patients with type 2 diabetes. The company now needs Phase III data to determine whether amycretin can compete against Eli Lilly’s tirzepatide and retatrutide for market share in the growing weight loss drug market. These Phase III trials will be tested across multiple dose levels of once-weekly subcutaneous amycretin.

Oral Amycretin — Oral Versions & Phase II Results

Novo Nordisk has also developed oral versions of amycretin, which completed Phase II study evaluation. The oral amycretin pill showed weight loss in early readouts, positioning the company to pursue a dual-formulation strategy. An oral arm gives Novo a non-injectable formulation to study alongside the subcutaneous programme, which could broaden the eventual label envelope. The oral amycretin programme is expected to enter its own Phase III for obesity, though Novo has not confirmed exact timing.

The development of both SC amycretin and oral amycretin gives Novo Nordisk flexibility in how the drug ultimately reaches the market. Regulatory authorities typically review each formulation separately, meaning the company could launch the subcutaneous version first while the oral pill completes Phase III. This phased launch strategy has been successfully demonstrated by Novo Nordisk with semaglutide (Ozempic injection followed by Rybelsus oral pill).

Clinical Trials & Phase III Data Expectations

Phase II Study Results — What Amycretin Has Demonstrated

In the Phase II study, SC amycretin was tested over 36 weeks in adults with type 2 diabetes and overweight or obesity. From a mean baseline body weight of 99.2 kg, the trial demonstrated weight loss of up to 14.6% on the highest 40 mg dose (vs 2.1% on placebo), alongside dose-dependent HbA1c reductions of up to 1.71 percentage points from a 7.8% baseline, with 89.1% of participants reaching HbA1c below 7% (data presented at the ADA 2026 Scientific Sessions). These Phase II results were reviewed favourably by the investment community and positioned amycretin as a serious competitor in the weight loss drug development pipeline.

The clinical trials also assessed safety: the most common adverse events reported with amycretin were gastrointestinal, consistent with the GLP-1 receptor agonist drug class. Most events were mild to moderate, and most gastrointestinal effects faded over the first 8–12 weeks of dosing as trial participants tolerated escalation. Novo Nordisk reported lower discontinuation than placebo-controlled comparator arms in adjacent weight-loss programmes.

Phase III Trials — Primary Endpoint & Regulatory Requirements

For the Phase III programme, regulatory authorities including the FDA and EMA will require Novo Nordisk to demonstrate that amycretin produces statistically significant weight loss compared with placebo in patients with obesity or overweight with at least one weight-related comorbidity. The primary endpoint in Phase III obesity trials is typically percentage body weight change from baseline at week 68 compared to placebo. The company must also demonstrate an acceptable safety profile across a larger patient population to determine the drug’s overall benefit-risk balance.

Investor expectations for Novo Nordisk’s Phase III amycretin trials are high. Analysts expect SC amycretin to demonstrate weight loss exceeding 20% at the highest doses tested, based on early results from the Phase II study and the compound’s dual mechanism of action. If amycretin achieves higher efficacy than semaglutide in Phase III, it could reshape the competitive landscape and capture significant market share for Novo Nordisk in the weight loss drug market.

Novo Nordisk, Market Competition & the Weight Loss Drug Landscape

Sales Projections & Market Access

The obesity drug market is projected to exceed USD 100 billion in annual sales by 2030, and Novo Nordisk is positioning amycretin to capture a significant share. The company currently dominates GLP-1 receptor agonist sales through Ozempic and Wegovy, but faces growing competition from Eli Lilly’s tirzepatide (Mounjaro/Zepbound) and an expanding pipeline of next-generation compounds. Market access for obesity drugs remains constrained globally, with insurance coverage limits and high out-of-pocket costs restricting the addressable population to a fraction of those who meet label criteria.

Novo Nordisk’s amycretin launch timing could be critical. If SC amycretin clears regulatory review, the company could launch by 2028–2029, entering a market where multiple new weight-loss drugs are expected to compete. Novo’s established manufacturing, distribution, and commercial infrastructure gives the company an advantage in bringing the drug to market quickly. Novo has also signalled that pricing and payer-access strategy will be central to the amycretin launch, with the goal of expanding the addressable population beyond the current GLP-1 cohort.

Amycretin vs Competing Pipeline Compounds

Amycretin faces competition from several pipeline drugs in Phase III development. Pfizer, Roche, and Viking Therapeutics are all developing oral or injectable weight loss drugs that could launch in a similar timeframe. Compared with CagriSema (Novo Nordisk’s own combination drug), SC amycretin offers a simpler single-molecule approach. Compared with Eli Lilly’s retatrutide, amycretin targets different receptor pathways (GLP-1/amylin vs GLP-1/GIP/glucagon), making direct efficacy comparisons difficult until head-to-head trials are conducted.

The competitive review of Novo Nordisk’s pipeline shows that the company is hedging its obesity strategy across multiple compounds: semaglutide (established market leader), CagriSema (combination approach), and amycretin (unimolecular approach). This diversified development pipeline ensures Novo Nordisk maintains relevance regardless of which molecular approach ultimately demonstrates the highest efficacy and best safety profile in Phase III trials.

How Amycretin Works in the Brain & Body — Mechanism of Action

Amylin Receptor Agonist Activity in the Brain

Zenagamtide’s amylin receptor agonist activity targets satiety centres in the brain, particularly the area postrema and nucleus tractus solitarius. These brain regions regulate appetite and food intake. By activating amylin receptors in the brain alongside GLP-1 receptors, the compound produces dual appetite suppression that has shown greater weight loss in trial readouts than GLP-1 monoagonist comparator arms. The amylin receptor agonist component also affects gastric emptying and insulin secretion, signals investigators track alongside body-weight endpoints.

Insulin regulation is the second leg of the mechanism. The GLP-1 receptor agonist activity enhances glucose-dependent insulin secretion, improving glycaemic readouts in trial participants with type 2 diabetes. This dual investigational mechanism—central appetite suppression plus peripheral insulin sensitivity—is how investigators have explained the weight-loss-plus-HbA1c profile seen across the 36-week Phase 2 cohort.

Trial Eligibility & Research Endpoints

Phase 3 enrolment criteria typically include adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia. The compound is dosed as a once-weekly subcutaneous injection in trial protocols, which simplifies adherence relative to daily-dosing comparator arms. Novo Nordisk will need to determine through Phase 3 readouts which sub-populations show the strongest response, where the dose-titration curve plateaus, and whether the safety profile holds across the cohorts exposed to the highest investigational dose.

As amycretin moves through development toward expected launch, Novo Nordisk will also need to publish trial protocols, dose-escalation data, and long-term safety findings to support a regulatory submission. The FDA / EMA review of Phase 3 data will determine whether amycretin earns approval in obesity, type 2 diabetes, or both indications—a decision that will shape market access, sales projections, and the company’s competitive position in the weight-loss drug market.